1. Home
  2. /
  3. Studies & Reports

Studies & Reports


June 2019

Community Oncology Alliance Announces ‘OCM 2.0’ Proposal, an Ambitious Reform Model to Improve Cancer Care and Reduce Costs

PTAC Application Demonstrates Community Oncology’s Continued Leadership in Providing Solutions to Cancer Care Cost and Quality Challenges The Community Oncology Alliance (COA) has submitted an innovative and ambitious reform model to improve quality, reduce costs, and provide important additional cancer care services to patients, caregivers, and survivors. Known as the “OCM 2.0”, the detailed

Download (PDF) Read Full
June 2019

COA Comments on the ICER Value Assessment Framework

Institute for Clinical and Economic Review Two Liberty Square Ninth Floor Boston, MA 02109 On behalf of the Board of Directors of the Community Oncology Alliance (COA), I would like to thank you for inviting the Community Oncology Alliance (COA) to provide suggestions for the 2020 Patient Guide of the ICER Value Assessment Framework. COA welcomes the opportunity

Download (PDF) Read Full
April 2019

CPAN at 10: A decade of Education, Advocacy, and IMPACT

Ten years ago, the Community Oncology Alliance (COA) created the Patient Advocacy Network (CPAN) to provide a powerful advocacy voice and forum for patients, survivors, caregivers, and others served by independent community oncology. The idea behind CPAN was simple: every individual who interacts with community oncology has a unique story to tell, formed by

Download (PDF) Read Full
April 2019

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

Oncology treatment advances continue to evolve at a rapid pace, with immuno-oncology (I-O) therapy at the forefront given its efficacy and tolerability across different tumor types. The last few years have seen fast-track approvals, promising clinical responses, and significant investment from both pharmaceutical companies and venture capital firms. Various forms of I-O therapy exist,

Download (PDF) Read Full
January 2019

COA comment letter on CMS plans to “modernize” the Part D program and Medicare Advantage (MA) plans

Submitted electronically to: http://www.regulations.gov The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P P.O. Box 8013 Baltimore, MD 21244-8013 Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses; CMS-4180-P Dear Administrator Verma: On behalf of the

Download (PDF) Read Full
October 2018

Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting

Florida Cancer Specialists and Research Institute, Gainesville; Xcenda, Palm Harbor, FL; and IntrinsiQ, Fresno, AZ Corresponding author: Lucio Gordan, MD, Florida Cancer Specialists and Research Institute, Division of Quality and Informatics, 6420 W Newberry Rd, Suite 100, Gainesville, FL 32605; e-mail: lgordan@flcancer.com. Disclosures provided by the authors are available with this article at jop.ascopubs.org.

Download (PDF) Read Full
September 2018

COA Submits Formal Comments on HOPPS Proposed Rule

Submitted electronically to: http://www.regulations.gov The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1695-P P.O. Box 8016 Baltimore, MD 21244-8013 Re: Medicare Program: Proposed Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Requests for Information on Promoting

Download (PDF) Read Full
August 2018

Pharmacy Benefit Manager Horror Stories – Part IV

The cautionary tale of the Pharmacy Benefit Manager (PBM) system is a lesson not yet learned. The United States’ health care system continues to be strangled by the dark presence of these ever-growing corporate middlemen, siphoning off billions of dollars in profits while leaving behind pain, suffering, anxiety, and despair for the millions of

Download (PDF) Read Full
July 2018

Community Oncology Alliance Submits Formal Comments on President’s Blueprint to Reduce Drug Prices

RE: Request for Information on U.S. Department of Health and Human Services (HHS) Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (CMS-2018-0075-0001) On behalf of the Board of Directors of the Community Oncology Alliance (COA), I am submitting this comment letter in response to the U.S. Department of Health and Human Services (HHS)

Download (PDF) Read Full
May 2018

COA Physician Survey: Medicare Part B Proposals Will Harm Patients, Increase Costs and Bureaucracy

Recently, the Medicare Payment Advisory Commission (MedPAC) and other stakeholders have proposed changes to the Medicare Part B drug reimbursement policy. Two suggested approaches include: Revamping the previously tested Part B Competitive Acquisition Program, now dubbed by MedPAC, as the “Drug Value Program” (DVP). The DVP is described as a pharmacy benefit manager (PBM)

Download (PDF) Read Full